CLX

Business Profile & Competitive Position

The Clorox Company sits in the Consumer Defensive sector, specifically the Household & Personal Products industry. It is a multinational manufacturer and marketer of consumer and professional products, reporting fiscal 2026 net sales of $6.7 billion with roughly 9,200 employees operating in approximately 25 countries and selling into about 95 markets. The consumer brand list includes Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt's Bees, while professional products are sold under Purell, CloroxPro, and CloroxHealthcare. The April 2026 acquisition of GOJO Industries expanded its health and hygiene footprint and strengthened its business-to-business presence.

The supplied profitability metrics paint a mixed picture of competitive strength. A net margin of 8.7% indicates the business is still converting sales into profit, but it is a mid-tier reading rather than evidence of a dominant pricing-power moat. The reported return on equity of -1893.5% is an extreme outlier that is not economically meaningful in the usual ROE framework; it almost certainly reflects a very small or negative shareholders' equity denominator rather than an operating result. Two structural pressures are also visible: customer concentration, with Walmart accounting for 26% of fiscal 2026 net sales and the five largest customers representing about half of consolidated net sales; and the January 31, 2026 expiration of the Glad bags and wraps venture with P&G, after which Clorox purchased P&G's 20% interest while Glad retained core intellectual property licenses on a royalty-free basis.

Financial Posture

Clorox currently carries an $11.3 billion market capitalization and trades at a P/E of 19.3 according to the supplied snapshot. That multiple sits in the middle-to-lower range for a household-products peer group, reflecting the earnings compression described in the 10-K excerpts. The stock's beta is 0.54, consistent with a defensive, low-correlation consumer staple. At $93.06, the shares register an RSI of 30.1, near technical oversold territory, and trade below the 50-day exponential moving average of $100.14.

The 8.7% net margin confirms the business is profitable, but the -1893.5% ROE is unusable as a standalone return metric at this magnitude. When ROE prints a quadruple-digit negative number, the figure is usually being driven by a shrunken or negative equity base rather than by operational destruction; investors typically look to margin, EBITDA, or free-cash-flow generation for a cleaner read. On the valuation side, a 19.3 P/E on $6.7 billion in fiscal 2026 sales and an $11.3 billion market cap suggests the market is pricing in a gradual recovery from the 26% diluted EPS decline rather than a breakout.

Strategic Priorities & Outlook

Clorox's latest 10-K frames the near-term agenda around a strategy called IGNITE, built on four choices: fuel long-term profitable growth, innovate consumer experiences, reimagine how the company and its people work, and continuously evolve the product portfolio. Operationally, management is focused on completing and optimizing a new enterprise resource planning (ERP) system and broader digital transformation, with the goal of generating long-term efficiencies across supply chain, digital commerce, innovation, and brand building.

The company also plans to invest in strong brands, strategic digital capabilities, and a streamlined operating model to build a more resilient organization capable of delivering consistent, profitable growth. Health and hygiene expansion is another priority, highlighted by the GOJO integration and a push to grow in professional and institutional markets.

Those priorities are set against a weaker fiscal 2026 backdrop: organic sales and earnings both declined, with diluted EPS down 26%. Some of that drop was attributed to macro headwinds and ERP transition timing that had pulled some sales into fiscal 2025. The strategic question is whether the ERP rollout, GOJO integration, and portfolio streamlining can offset the revenue-timing drag and customer concentration as Clorox enters fiscal 2027.

Macro & Geopolitical Exposure

As a Consumer Defensive / Household & Personal Products company, Clorox is exposed to stable end demand but persistent input-cost volatility. Resins, chemicals, pulp and paper, packaging materials, and energy are significant cost buckets for cleaning products, bags and wraps, and charcoal. When those input costs rise, margins compress unless pricing and cost savings fully offset them. The September 3, 2026 zacks.com headline, "Can Cost Savings Offset Inflation & Protect Clorox's Margins?", captures the exact tension facing the business.

Trade policy matters because packaging components, raw materials, and finished goods may cross borders, exposing margins to tariffs or supply-chain disruptions. With operations in roughly 25 countries and sales in about 95 markets, currency translation is a recurring factor in reported results. Retail concentration is another macro-style risk: Walmart represented 26% of fiscal 2026 net sales, and the top five customers accounted for about half of sales, giving large retailers meaningful bargaining leverage. Regulation is also a fixture of this industry, with disinfectants, sanitizers, water-filtration products, and health-oriented SKUs subject to EPA, FDA, and state-level oversight, while packaging-waste and plastics rules are tightening in multiple jurisdictions.

Recent Developments

Recent news flow has centered on valuation, margins, and post-earnings price action. On September 3, 2026, zacks.com asked whether Clorox's cost savings can offset inflation and defend margins. A day earlier, on September 2, 2026, zacks.com noted that CLX had fallen 9.3% since its last earnings report and questioned whether the stock can rebound. On September 1, 2026, zacks.com compared Clorox with Koninklijke Ahold Delhaize (ADRNY) in a value-stock matchup. Meanwhile, on August 31, 2026, defenseworld.net reported that the Canada Pension Plan Investment Board acquired 32,488 shares of The Clorox Company.

Taken together, the headlines show a defensive staples name under margin scrutiny after a sharp pullback, with at least one large Canadian pension plan adding exposure. The 9.3% decline and the August 31 institutional purchase frame the current debate: whether the recent weakness is a value opportunity or a signal that earnings headwinds are not fully priced.

Earnings Behavior & Post-Earnings Drift

Clorox has beaten the market's real expectation in six of the last eight reported quarters, a 75% beat rate, with an average earnings surprise of 9.6%. Across those eight quarters, the average five-day price move after earnings has been 1.67% to the upside, classified as an "up" drift.

The last four quarters show how volatile the post-earnings reaction can be even when the headline surprise is positive. On August 3, 2026, the company reported $1.66 versus a $1.64 estimate (1.2% surprise), and the stock rose 6.52% the next day and 9.61% over the following five days. Before that, on April 30, 2026, Clorox beat by 5.8% ($1.64 actual versus $1.55 estimated) yet fell 9.67% the next session and 4.49% over the next five days. On February 3, 2026, it missed by 2.8% ($1.39 versus $1.43) but still gained 2.43% the next day and 5.63% over five days. On November 3, 2025, it delivered $0.85 versus a $0.818 estimate (3.9% beat), rising 1.17% the next day before dropping 4.08% over the next five days. The next scheduled report is November 3, 2026, after the market close, with a consensus EPS estimate of $1.11. The history shows that beats do not guarantee positive price reactions and that the post-earnings window can produce sizable moves in both directions.

For a deeper dive into how institutional analysts are modeling margin recovery, the GOJO integration, and the next earnings catalyst on November 3, 2026, review the full institutional verdict and consensus breakdown.